Share Price and Basic Stock Data
Last Updated: January 12, 2026, 3:16 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MPS Pharmaa Ltd operates in the pharmaceuticals sector, focusing on developing and marketing healthcare products. The company reported a stagnant revenue trend, with sales standing at ₹0.00 for the past several quarters, including the periods of Mar 2023 and Mar 2024. This lack of revenue generation raises concerns about the company’s operational viability. Historically, MPS Pharmaa Ltd experienced a significant decline in sales from ₹30.27 Cr in Mar 2014 to ₹0.00 by Mar 2024, marking a stark downward trajectory. The company has not reported any operational revenue in recent years, suggesting severe challenges in its business model or market positioning. Such performance starkly contrasts with typical industry standards, where companies often exhibit steady revenue growth. The absence of sales highlights the urgent need for MPS Pharmaa to reassess its strategies and operational efficiency to revive its revenue streams and regain market competitiveness.
Profitability and Efficiency Metrics
MPS Pharmaa’s profitability metrics reflect a challenging financial landscape. The operating profit has consistently reported negative figures, with the latest figure for Mar 2025 at -₹0.77 Cr. The company has faced mounting operating losses since Mar 2014, with the operating profit margin (OPM) reflecting severe operational inefficiencies. The interest coverage ratio (ICR) stood at an alarming -1438.08x, indicating an inability to meet interest obligations from earnings. Furthermore, the net profit margin has also been negative across the reporting periods, culminating in a net profit of -₹0.90 Cr for Mar 2025. This persistent lack of profitability raises significant concerns about the company’s sustainability, particularly in a highly competitive sector where maintaining profit margins is critical for survival. MPS Pharmaa’s return on equity (ROE) of 59.0% may appear attractive superficially, but it is misleading given the underlying losses, emphasizing the need for a strategic turnaround.
Balance Sheet Strength and Financial Ratios
The balance sheet of MPS Pharmaa Ltd reveals a precarious financial position, characterized by negative reserves amounting to -₹18.47 Cr as of Sep 2025. The company’s total borrowings stood at ₹7.51 Cr, leading to a total debt-to-equity ratio of 6.90, indicating a highly leveraged position. This level of leverage is concerning, especially in the context of the company’s ongoing operational losses. The current ratio of 0.25 and quick ratio of 0.19 reflect liquidity challenges, suggesting that the company may struggle to meet short-term obligations. Additionally, the book value per share has declined to ₹0.56, down from ₹2.07 in Mar 2021, highlighting deteriorating asset value. With the enterprise value reported at ₹13.53 Cr, it becomes evident that the market is evaluating MPS Pharmaa with caution, given its significant operational and financial challenges. The financial ratios indicate a need for immediate corrective measures to restore financial health and investor confidence.
Shareholding Pattern and Investor Confidence
The shareholding pattern of MPS Pharmaa Ltd indicates a predominantly public investor base, with 63.52% of shares held by the public as of Dec 2024. Promoters hold a significant stake of 35.89%, which has remained stable over several reporting periods. However, the presence of foreign institutional investors (FIIs) is notably absent, with domestic institutional investors (DIIs) holding a mere 0.58%. This lack of institutional backing may reflect broader market skepticism regarding the company’s prospects. The number of shareholders has slightly fluctuated, standing at 4,433 as of Sep 2025, indicating some level of investor retention despite the operational challenges. The high public shareholding could imply potential volatility in stock performance, especially during adverse financial periods. Overall, the shareholding structure suggests a cautious investor sentiment, with a significant reliance on retail investors who may be more susceptible to market fluctuations.
Outlook, Risks, and Final Insight
The outlook for MPS Pharmaa Ltd remains uncertain, primarily due to its ongoing revenue stagnation and operational losses. The company faces significant risks, including liquidity challenges, high leverage, and the absence of institutional investor confidence. A strategic overhaul is necessary to address these issues, potentially involving a reassessment of its business model, exploring new market avenues, or enhancing operational efficiencies. On the upside, if MPS Pharmaa can successfully pivot towards profitability and stabilize its financial position, it could regain investor interest and market share. However, the risks of continued operational losses pose a significant threat to its sustainability. The management’s ability to navigate these challenges will be critical in determining the company’s future trajectory, emphasizing the need for decisive action and strategic planning to secure a turnaround and restore investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 125 Cr. | 99.1 | 208/84.3 | 27.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,145 Cr. | 380 | 479/192 | 85.8 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.5 Cr. | 40.0 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,306.03 Cr | 1,128.86 | 52.39 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.24 | 0.23 | 0.31 | 0.19 | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 | 0.19 |
| Operating Profit | -0.24 | -0.23 | -0.31 | -0.19 | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 | -0.19 |
| OPM % | |||||||||||||
| Other Income | 0.00 | 0.00 | 0.02 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.28 | -0.27 | -0.33 | -0.20 | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 | -0.23 |
| Tax % | 0.00% | 0.00% | -3.03% | -5.00% | -5.26% | -4.55% | 0.00% | -4.35% | -4.35% | 0.00% | 21.74% | -4.35% | -4.35% |
| Net Profit | -0.27 | -0.26 | -0.32 | -0.19 | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 | -0.22 |
| EPS in Rs | -0.14 | -0.14 | -0.17 | -0.10 | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 | -0.12 |
Last Updated: January 6, 2026, 8:06 pm
Below is a detailed analysis of the quarterly data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.19 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.19 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.19 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.19 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.23 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.23 Cr..
- For Tax %, as of Sep 2025, the value is -4.35%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -4.35%.
- For Net Profit, as of Sep 2025, the value is -0.22 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.22 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.12. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.75 |
| Operating Profit | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.75 |
| OPM % | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| Other Income | 0.01 | 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 |
| Interest | 1.20 | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -0.87 |
| Tax % | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | |
| Net Profit | 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -0.89 |
| EPS in Rs | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -247.83% | -75.00% | -521.01% | 88.23% | -43.68% | 6.40% | -277.78% | 96.83% | -650.00% | 20.95% | -8.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 172.83% | -446.01% | 609.24% | -131.91% | 50.08% | -284.18% | 374.61% | -746.83% | 670.95% | -29.39% |
MPS Pharmaa Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | -24% |
| 5 Years: | -44% |
| 3 Years: | -39% |
| Last Year: | -59% |
Last Updated: September 5, 2025, 3:51 pm
Balance Sheet
Last Updated: December 4, 2025, 3:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 5.05 | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -18.47 |
| Borrowings | 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.51 |
| Other Liabilities | 6.52 | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.84 |
| Total Liabilities | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
| Fixed Assets | 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.74 |
| CWIP | 0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.65 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 2.06 |
| Total Assets | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
Below is a detailed analysis of the balance sheet data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.11 Cr..
- For Reserves, as of Sep 2025, the value is -18.47 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -18.03 Cr. (Mar 2025) to -18.47 Cr., marking a decline of 0.44 Cr..
- For Borrowings, as of Sep 2025, the value is 7.51 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 7.46 Cr. (Mar 2025) to 7.51 Cr., marking an increase of 0.05 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.84 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.80 Cr. (Mar 2025) to 0.84 Cr., marking an increase of 0.04 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.99 Cr.. The value appears to be improving (decreasing). It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.74 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Mar 2025) to 3.74 Cr., marking a decrease of 0.09 Cr..
- For CWIP, as of Sep 2025, the value is 2.65 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 2.65 Cr., marking a decrease of 0.26 Cr..
- For Investments, as of Sep 2025, the value is 0.54 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.54 Cr..
- For Other Assets, as of Sep 2025, the value is 2.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.06 Cr..
- For Total Assets, as of Sep 2025, the value is 8.99 Cr.. The value appears to be declining and may need further review. It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
However, the Borrowings (7.51 Cr.) are higher than the Reserves (-18.47 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.38 | -6.97 | -7.14 | -9.78 | -3.43 | -3.24 | -3.20 | -9.82 | -6.49 | -7.72 | -8.07 | -8.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | |||||
| Inventory Days | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | ||||
| Days Payable | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | ||||
| Cash Conversion Cycle | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | |||||
| Working Capital Days | 99.72 | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | |||||
| ROCE % | 8.18% | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.47 | -0.43 | -0.55 |
| Diluted EPS (Rs.) | -0.47 | -0.43 | -0.55 |
| Cash EPS (Rs.) | -0.39 | -0.35 | -0.47 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 |
| PBDIT / Share (Rs.) | -0.37 | -0.36 | -0.48 |
| PBIT / Share (Rs.) | -0.45 | -0.44 | -0.56 |
| PBT / Share (Rs.) | -0.45 | -0.44 | -0.56 |
| Net Profit / Share (Rs.) | -0.46 | -0.43 | -0.54 |
| Return on Networth / Equity (%) | -83.08 | -42.21 | -37.63 |
| Return on Capital Employeed (%) | -68.24 | -38.85 | -35.47 |
| Return On Assets (%) | -9.62 | -8.36 | -10.31 |
| Total Debt / Equity (X) | 6.90 | 3.69 | 2.42 |
| Current Ratio (X) | 0.25 | 0.27 | 0.29 |
| Quick Ratio (X) | 0.19 | 0.20 | 0.22 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.08 |
| Interest Coverage Ratio (X) | -1438.08 | -563.32 | -1722.46 |
| Interest Coverage Ratio (Post Tax) (X) | -1800.93 | -662.72 | -1955.76 |
| Enterprise Value (Cr.) | 13.53 | 13.40 | 10.77 |
| EV / EBITDA (X) | -18.88 | -19.00 | -11.65 |
| Price / BV (X) | 5.63 | 3.12 | 1.44 |
| EarningsYield | -0.14 | -0.13 | -0.26 |
After reviewing the key financial ratios for MPS Pharmaa Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.39. This value is below the healthy minimum of 3. It has decreased from -0.35 (Mar 24) to -0.39, marking a decrease of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.37. This value is below the healthy minimum of 2. It has decreased from -0.36 (Mar 24) to -0.37, marking a decrease of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 2. It has decreased from -0.43 (Mar 24) to -0.46, marking a decrease of 0.03.
- For Return on Networth / Equity (%), as of Mar 25, the value is -83.08. This value is below the healthy minimum of 15. It has decreased from -42.21 (Mar 24) to -83.08, marking a decrease of 40.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is -68.24. This value is below the healthy minimum of 10. It has decreased from -38.85 (Mar 24) to -68.24, marking a decrease of 29.39.
- For Return On Assets (%), as of Mar 25, the value is -9.62. This value is below the healthy minimum of 5. It has decreased from -8.36 (Mar 24) to -9.62, marking a decrease of 1.26.
- For Total Debt / Equity (X), as of Mar 25, the value is 6.90. This value exceeds the healthy maximum of 1. It has increased from 3.69 (Mar 24) to 6.90, marking an increase of 3.21.
- For Current Ratio (X), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 1.5. It has decreased from 0.27 (Mar 24) to 0.25, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.20 (Mar 24) to 0.19, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1,438.08. This value is below the healthy minimum of 3. It has decreased from -563.32 (Mar 24) to -1,438.08, marking a decrease of 874.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1,800.93. This value is below the healthy minimum of 3. It has decreased from -662.72 (Mar 24) to -1,800.93, marking a decrease of 1,138.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.53. It has increased from 13.40 (Mar 24) to 13.53, marking an increase of 0.13.
- For EV / EBITDA (X), as of Mar 25, the value is -18.88. This value is below the healthy minimum of 5. It has increased from -19.00 (Mar 24) to -18.88, marking an increase of 0.12.
- For Price / BV (X), as of Mar 25, the value is 5.63. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 5.63, marking an increase of 2.51.
- For EarningsYield, as of Mar 25, the value is -0.14. This value is below the healthy minimum of 5. It has decreased from -0.13 (Mar 24) to -0.14, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MPS Pharmaa Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -68.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -83.08% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1800.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.19
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 6.9
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 138, Roz-Ka-Meo Industrial Area, Sohna, Mewat Dist. Haryana 122103 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Peeyush Kumar Aggarwal | Managing Director |
| Mr. Ram Niwas Sharma | Non Independent Director |
| Ms. Madhu Sharma | Independent Director |
| Mr. Ajay Sharma | Independent Director |
FAQ
What is the intrinsic value of MPS Pharmaa Ltd?
MPS Pharmaa Ltd's intrinsic value (as of 12 January 2026) is ₹2.38 which is 41.67% higher the current market price of ₹1.68, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3.21 Cr. market cap, FY2025-2026 high/low of ₹4.29/1.68, reserves of ₹-18.47 Cr, and liabilities of ₹8.99 Cr.
What is the Market Cap of MPS Pharmaa Ltd?
The Market Cap of MPS Pharmaa Ltd is 3.21 Cr..
What is the current Stock Price of MPS Pharmaa Ltd as on 12 January 2026?
The current stock price of MPS Pharmaa Ltd as on 12 January 2026 is ₹1.68.
What is the High / Low of MPS Pharmaa Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MPS Pharmaa Ltd stocks is ₹4.29/1.68.
What is the Stock P/E of MPS Pharmaa Ltd?
The Stock P/E of MPS Pharmaa Ltd is .
What is the Book Value of MPS Pharmaa Ltd?
The Book Value of MPS Pharmaa Ltd is 0.33.
What is the Dividend Yield of MPS Pharmaa Ltd?
The Dividend Yield of MPS Pharmaa Ltd is 0.00 %.
What is the ROCE of MPS Pharmaa Ltd?
The ROCE of MPS Pharmaa Ltd is 9.79 %.
What is the ROE of MPS Pharmaa Ltd?
The ROE of MPS Pharmaa Ltd is 59.0 %.
What is the Face Value of MPS Pharmaa Ltd?
The Face Value of MPS Pharmaa Ltd is 10.0.